Waters (NYSE:WAT) Shares Unloaded Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Waters Corporation (NYSE:WAT). In a filing disclosed on March 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Waters stock on February 13th.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Linde (NASDAQ:LIN) on 2/18/2026.
• Purchased $1,001 – $15,000 in shares of First Citizens BancShares (NASDAQ:FCNCA) on 2/5/2026.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 2/5/2026.
• Purchased $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/29/2026.
• Sold $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/23/2026.
• Sold $15,001 – $50,000 in shares of Johnson & Johnson (NYSE:JNJ) on 1/23/2026.
• Sold $15,001 – $50,000 in shares of Markel Group (NYSE:MKL) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of General Motors (NYSE:GM) on 1/7/2026.

Waters Stock Performance

Shares of WAT stock opened at $302.31 on Wednesday. The firm’s 50 day moving average is $338.89 and its 200 day moving average is $351.53. The stock has a market capitalization of $29.66 billion, a P/E ratio of 28.07, a PEG ratio of 2.08 and a beta of 1.20. Waters Corporation has a 12 month low of $275.05 and a 12 month high of $414.15. The company has a current ratio of 1.73, a quick ratio of 1.27 and a debt-to-equity ratio of 0.37.

Waters (NYSE:WAT) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The business had revenue of $932.36 million for the quarter, compared to analysts’ expectations of $928.17 million. During the same quarter in the previous year, the firm posted $4.10 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, sell-side analysts anticipate that Waters Corporation will post 12.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on WAT. Barclays began coverage on Waters in a report on Tuesday, February 10th. They set an “overweight” rating and a $400.00 price objective on the stock. UBS Group cut their price objective on shares of Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Wall Street Zen cut shares of Waters from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a report on Wednesday, January 21st. Finally, HSBC initiated coverage on shares of Waters in a report on Tuesday, January 27th. They issued a “buy” rating and a $460.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $393.84.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mondrian Investment Partners LTD purchased a new position in shares of Waters during the third quarter valued at approximately $1,397,000. Mackenzie Financial Corp grew its stake in shares of Waters by 12.2% in the 3rd quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock worth $69,512,000 after buying an additional 25,182 shares during the last quarter. Vanguard Group Inc. increased its position in Waters by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock valued at $2,295,612,000 after buying an additional 246,128 shares in the last quarter. Alberta Investment Management Corp purchased a new position in Waters during the third quarter valued at $4,677,000. Finally, Veritas Asset Management LLP purchased a new position in Waters during the third quarter valued at $175,320,000. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Waters

In related news, Director Wei Jiang bought 500 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were purchased at an average cost of $289.46 per share, with a total value of $144,730.00. Following the completion of the purchase, the director owned 3,441 shares in the company, valued at approximately $996,031.86. The trade was a 17.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.82% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.